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Abstract: We previously reported that AR phosphorylation at serine 213 was associated 
with poor outcome and may contribute to prostate cancer development and progression. 
This study investigates if specific AR phosphorylation sites have differing roles in the 
progression of hormone naïve prostate cancer (HNPC) to castrate resistant disease (CRPC). 
A panel of phosphospecific antibodies were employed to study AR phosphorylation in 84 
matched HNPC and CRPC tumours. Immunohistochemistry measured Androgen receptor 
expression phosphorylated at serine residues 94 (pAR94), 308 (pAR308), 650(pAR650) and 791 
(pAR791). No correlations with clinical parameters were observed for pAR94 or pAR650 in 
HNPC or CRPC tumours. In contrast to our previous observation with serine 213,  
high pAR308 is significantly associated with a longer time to disease specific death  
(p = 0.011) and high pAR791 expression significantly associated with a longer time to 
disease recurrence (p = 0.018) in HNPC tumours and longer time to death from disease 
recurrence (p = 0.040) in CRPC tumours. This observation in CRPC tumours was 
attenuated in high apoptotic tumours (p = 0.022) and low proliferating tumours (p = 0.004). 
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These results demonstrate that understanding the differing roles of AR phosphorylation is 
necessary before this can be exploited as a target for castrate resistant prostate cancer. 
Keywords: androgen receptor; phosphorylation; hormone naive prostate cancer; castrate 
resistant prostate cancer 
 
1. Introduction 
Prostate cancer has the highest cancer incidence in males and is the second highest cause of male 
cancer related mortality [1]. As a whole compared to other cancers, prostate cancer has a relatively low 
mortality rate. However if you consider only castrate resistant prostate cancer (CRPC), the mortality 
rate in these men is high and this is the main contributor to prostate cancer having the highest cause of 
male cancer related mortality.  
One of the most challenging problems in the management of prostate cancer is the treatment of 
patients who no longer respond to hormone therapy and have failed docetaxel chemotherapy. CRPC 
has evolved from the clinical observation that surgical or medical castration, by blocking the production of 
testicular androgens, is not curative and virtually all patients have prostate cancer disease recurrence.  
Current practice aims to inhibit androgen production and action, thereby reducing stimulation of the 
androgen receptor (AR). Inhibition of testicular androgen production is achieved surgically (bilateral 
orchidectomy) or chemically, using gonadotropin-releasing hormone (GnRH) agonists. The action of 
androgen may be blocked at a peripheral level using anti androgens, which inhibit ligand binding to 
AR and subsequent activation. Current clinical data implies that the AR is expressed and continues to 
mediate androgen signalling after failure of this therapeutic approach. However as this does not 
completely eliminate circulating androgens, sufficient concentrations of dihydrotestosterone may 
accumulate in tumour cells to maintain AR signalling, especially in the context of up-regulated 
receptor levels or increased sensitivity of the AR for activation. In addition, ligands of non-testicular 
origin (adrenal gland or the tumour cells themselves) or ligand-independent activation can contribute 
to continued AR signalling. To overcome this and to improve patient treatment options, the 
mechanisms underlying the development of castrate resistance must be fully understood.  
The AR not only functions as a transcription factor but also as a core that incorporates multiple 
extracellular signals. AR effects are influenced by their levels of expression and posttranslational 
modifications, including phosphorylation on serine [2–4] and tyrosine residues [5], sumoylation [6] 
and acetylation on lysine residues [7,8]. Many phosphorylation sites at serine and tyrosine residues on 
the AR have been identified in cell culture systems after different hormonal or growth factor 
stimulation [2–5,9]. Phosphorylation of AR is stimulated in a ligand dependent manner and also in a 
ligand independent manner through signal transduction cascades. Phosphorylation of serine residues 
stabilizes the AR and protects it from proteolytic degradation. In response to androgen-binding, serine 
81 is the most frequently phosphorylated site on the AR, giving the highest stoichiometric phosphorylation 
yield in LNCaP cells treated with androgens. This phosphorylation has been associated with AR 
stability and transcriptional activity and regulates promoter selectivity [10,11]. It is also associated 
with prostate cancer cell growth in cell line studies, suggesting some significance of AR Serine 81 
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phosphorylation in AR function [12]. AR transcriptional activity can be induced by EGF, and is 
dependent on AR phosphorylation at serines 515 (MAPK consensus site) and 578 (PKC consensus site), 
which regulates nuclear cytoplasmic shuffling of the AR, through interactions with the  
Ku-70/80 regulatory subunits of DNA-dependent protein kinase [3]. Phosphorylation of the AR at 
serine residues 213 and 791 is predicted to be mediated by Akt, which results in increased AR 
transactivation [13]. We have previously reported that the expression and activation of the PI3K/Akt 
cascade influences the progression to castrate resistant disease using clinical prostate cancer tumours, 
where phosphorylation of AR at the Akt consensus site serine 213 was significantly associated with 
disease progression [14,15]. The aim of the current study was to establish if other AR phosphorylation 
sites are associated with patient survival and additionally determine if inhibition or activation at these 
phosphorylation sites could be employed as therapeutic targets. A number of phosphoserine-specific 
antibodies have been described for the AR [3,16–18] and the availability of these antibodies provides 
the possibility of screening clinical samples for changes in receptor phosphorylation, which is of 
utmost importance for a fuller understanding of the role of this chemical modification in prostate 
cancer disease progression and may be utilized to predict response to abiraterone. 
2. Results and Discussion 
2.1. Clinico-Pathological Detail 
Clinical data recorded for each patient included age (70, IQR 66–74), prostate specific antigen 
(PSA) at diagnosis (34.5 ng/mL, IQR 8.5–126.2), PSA at disease recurrence (16 ng/mL, IQR 4.7–39.5) 
and Gleason grade at diagnosis (7 range 6–9) and at disease recurrence (9 range 8–9). All patients 
underwent disease recurrence (median time to disease recurrence 2.88 years, IQR 1.83–4.71 years). 
The median time to death from disease recurrence was 2.1 (IQR 1.02–3.51) years. The median survival 
time was 5.82 (IQR 3.44–7.35) years. At last follow-up, 9 patients were alive, 53 patients had died of 
prostate cancer and 21 patients had died of causes not attributed to prostate cancer. Patients in this 
cohort were diagnosed with locally advanced (51) or metastatic prostate cancer (30) and subsequently 
received chemical or surgical castration (27 sub capsular bilateral orchidectomy, 55 GnRH analogue,  
2 had both). 57 of the 84 patients also received anti androgen therapy, this included all those who 
received GnRH analogues. Following disease recurrence, 31 patients received radiotherapy; no 
patients received taxane therapy. Clinical parameters associated with time to disease recurrence, time 
to death from disease recurrence and disease specific survival are shown in Table 1.  
Table 1. Impact of clinicopathological factors on patient survival. 
 
Time to disease 
recurrence 
Time to death from 
disease recurrence 
Disease specific 
survival 
Age p = 0.210 
p = 0.247 p = 0.246 
(<70/>70/unknown) (56/28) 
Gleason p = 0.020 
p = 0.165 p = 0.261 
(<7/=7/>7/unknown) (33/39/12) 
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Table 1. Cont. 
 
Time to disease 
recurrence 
Time to death from 
disease recurrence 
Disease specific 
survival 
Metastasis at diagnosis p = 0.007 
p = 0.016 p = 0.0007 
(No/Yes/Unknown) (66/18) 
PSA at diagnosis 
p = 0.044 
p = 0.246 p = 0.261 (<4/4–10/>10) 
unknown (3/13/68) 
Metastasis at recurrence 
 
p = 0.001 
p = 0.006 
(No/Yes/Unknown) (19/54/13) 
PSA at recurrence 
 
p = 0.019 
p = 0.001 (<10/10–20/>20) 
(37/11/36) 
unknown 
The strength of this patient cohort is the ability to investigate if changes in protein expression, in the 
transition from hormone naïve to castrate resistant disease are related to clinical outcome measures. 
Table 2 demonstrates that only two phosphorylation sites (pAR308 and pAR650 ) exhibited and increase 
in expression in the transition from hormone naïve to castrate resistant disease (Table 2).  
Table 2. Protein expression in hormone naїve and castrate resistant tumours: the median 
histoscore and interquartile range (IQR) for hormone naїve tumours (HNPC) and castrate 
resistant tumours (CRPC, tumours that have become refractory to hormone treatment) and 
the p value of these values compared using a Wilcoxon sign rank test. ICCC = interclass 
correlation coefficient. C and N relates to protein cellular location, C (cytoplasm) and N 
(nucleus). p before a protein indicates that the antibody detects phosphorylated protein and 
the number following the protein represents the serine site of phosphorylation. 
 HNPC (IQR) CRPC (IQR) p value ICCC 
pAR94, C 30 (0–50) 15 (0–36) p = 0.404 0.71 
pAR94, N 25 (10–39) 20 (9–38) p = 0.158 0.70 
pAR308, N 135 (110–153) 153 (140–173) p = 0.006 0.77 
pAR650, C 0 (0–15) 5 (0–11) p = 0.980 0.92 
pAR650, N 85 (44–110) 104 (74–125) p = 0.003 0.95 
pAR791, C 20 (0–50) 10 (0–33) p = 0.798 0.92 
pAR791, N 34 (16–62) 29 (12–54) p = 0.291 0.95 
2.2. Protein Expression in the Hormone Naïve Tumours 
To determine if protein expression was linked to time to biochemical relapse, Kaplan-Meier graphs 
were plotted for the hormone naïve tumours expressing low levels of protein (<median) versus high 
levels of protein (>median) and compared using the log rank test. Expression of pAR94, pAR308 and 
pAR650 was not associated with clinical parameters in our cohort. However patients with tumours that 
had high expression of pAR791in the cytoplasm had a significantly longer time to disease recurrence  
(as measured by time to biochemical relapse) than those patients whose tumours expressed low levels 
of pAR791 p = 0.018 (Figure 1). The median time to disease recurrence for those with low expression 
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was 2.3 (1.6–3.1) years compared to 3.2 years for high expression (0.8–5.6 years). These patients with 
high expression were two times more likely to have a longer time to relapse (HR = 2.1 (1.1–3.7)  
p = 0.02). High pAR 791 expression was demonstrated to be an independent prognostic marker by Cox 
regression analysis when compared with the significant clinical parameters PSA at diagnosis, Gleason 
grade at diagnosis, metastases at diagnosis and radiotherapy (p = 0.019). 
Figure 1. Kaplan Meier plot demonstrates that those patients whose tumours express high 
pAR791 in the cytoplasm (24 patients) have a longer time to disease recurrence than those 
patients whose tumours exhibit low pAR791 expression (25 patients). 
pAR791 cytoplasmic expression is associated with disease recurrence 
 
2.3. Protein Expression in the Castrate Resistant Tumours 
To establish if phosphorylated AR expression was linked to time to death from disease recurrence, 
Kaplan-Meier graphs were plotted for the castrate resistant tumours expressing low levels of 
phosphorylated AR (<median) versus high levels of phosphorylated AR (>median) and compared 
using the log rank test. Expression of pAR94 and pAR650 was not associated with clinical parameters in 
our cohort. However patients whose tumours expressed high levels of nuclear pAR308 were observed to 
have a significantly longer disease specific survival time compared to those patients whose tumours 
expressed low levels of nuclear pAR308 (p = 0.011, Figure 2).  
This observation of good prognosis was also observed for pAR791. Patients whose tumours 
expressed high levels of nuclear pAR791 were observed to have a significantly longer time to death 
from disease recurrence compared to those patients whose tumours expressed low levels of nuclear 
pAR791 p = 0.04 (Figure 3). These patients with high expression were two times more likely to have a 
longer survival period (HR = 1.9 (1.1–3.4) p = 0.04). High pAR791expression was demonstrated to be 
an independent prognostic marker by Cox regression analysis when compared with significant clinical 
parameters (p = 0.017). 
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Figure 2. Kaplan Meier plot demonstrates that those patients whose tumours express high 
nuclear pAR308 (34 patients) have a longer disease specific survival than those patients 
whose tumours exhibit low pAR308 expression (32 patients).  
pAR308 expression is associated with disease specific survival 
 
Figure 3. Kaplan Meier plot demonstrates that those patients whose tumours express high 
pAR791 in the nucleus (31 patients) have a longer time to death from disease recurrence 
than those patients whose tumours exhibit low nuclear pAR791 expression (32 patients). 
pAR791 nuclear expression is associated with time to death from disease recurrence 
 
2.3.1. Association of pAR791 Expression with Apoptosis and Proliferation 
As high expression of pAR791 is significantly associated with a longer time to disease recurrence 
and time to death from disease recurrence, it was investigated if this expression was linked with 
tumour apoptotic or proliferation index. Kaplan-Meier graphs were then plotted for the castrate 
resistant tumours expressing low levels of protein (<median) versus high levels of protein (>median), 
stratified by apoptotic or proliferation index and compared using the log rank test.  
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The association observed for pAR791 with a longer time to death from disease recurrence was 
negated in tumours with low apoptotic index (p = 0.784) and attenuated in tumours with a high 
apoptotic index (p = 0.022). The median time to death from disease recurrence for those with low 
pAR791 expression/high apoptosis was 1.5 years (1–2.2) years compared to 3.6 years (2.4–4.9 years) 
for those with high pAR791expression/high apoptosis (Figure 4A,B).  
Figure 4. (A) Kaplan Meier plot demonstrates that in patients with low apoptotic tumours, 
pAR791 expression is not associated with time to death from disease recurrence (low 
expression 19 patients, high expression 9 patients.); (B) Kaplan Meier plot demonstrates 
that in patients with highly apoptotic tumours, high pAR791 expression is significantly 
associated with longer time to death from disease recurrence than those with low pAR791 
expression (low expression 12 patients, high expression 13 patients.). 
pAR791 expression in tumours with low levels of apoptosis 
 
pAR791 expression in tumours with high levels of apoptosis 
 
The association observed for pAR791 with a longer time to death from disease recurrence was also 
attenuated in tumours with low proliferation index (p = 0.004) and negated in tumours with a high 
proliferation (p = 0.489). The median time to death from disease recurrence for those with low  
pAR791 expression/low proliferation index was 1.1 years (0.5–1.6) years compared to 3.4 years  
(2.4–4.3 years) for those with high pAR791 expression/low proliferation (Figure 5A,B). 
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Figure 5. (A) Kaplan Meier plot demonstrates that in patients with low proliferating 
tumours (8 patients), high pAR791 expression (12 patients) is significantly associated with 
longer time to death from disease recurrence than those with low pAR791 expression;  
(B) Kaplan Meier plot demonstrates that in patients with high proliferation tumours, 
pAR791 expression is not associated with time to death from disease recurrence  
(low expression 11 patients, high expression 12 patients). 
pAR791 expression in tumours with low levels of proliferation 
 
pAR791 expression in tumours with high levels of proliferation 
 
The role of pAR791 expression therefore appears greater in slow proliferating, apoptotic tumours. 
pAR308 expression was not associated with either tumour apoptosis or proliferation. 
2.3.2. Association of pAR791 Expression with AR Gene Amplification 
Data for AR gene amplification from the same cohort of patients was available for analysis. This 
allowed us to determine if AR amplification was associated with the phosphorylation levels of AR 
expression in this study. By dividing protein expression into tumours with or without AR 
amplification, tumours with AR amplification had significantly lower nuclear pAR791 expression 
compared to those without AR amplification (p = 0.034) (Figure 6). Median nuclear pAR791 
expression for castrate resistant tumours with AR amplification is 19 (IQR, 11–35) histoscore units 
compared to 39 (IQR, 19–69) histoscore units, for tumours that do not have AR amplification. 
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Figure 6. Box plot demonstrates that pAR791 expression is significantly lower in patients 
with AR amplification (non amplification 30 patients, amplification 18 patients). 
 
2.4. Discussion 
One of the many challenges in the effective management of prostate cancer is the identification of 
molecular markers capable of predicting disease progression. Castrate resistant disease represents the 
lethal phenotype of prostate cancer. The main aim of this study was to investigate the effect of 
androgen receptor phosphorylation in the development and progression of prostate cancer and to 
determine if it influenced patient outcome. Translating the in vitro evidence into the clinical scenario, 
this study established that phosphorylation at specific serine residues on the AR are involved in the 
development of castrate resistant disease.  
Utilizing this cohort, we have previously reported that phosphorylation of AR at serine 213 is 
associated with poor prognosis in CRPC [14,15] and it is accepted that in addition to protecting and 
stabilizing AR, phosphorylation of specific serine residues can influence a ligand-independent 
induction of transcription by the AR [19,20]. Therefore the ability of signaling cascades to influence 
AR function may play a significant role in the development and progression of prostate cancer. We, 
and others, have demonstrated that multiple signal transduction pathways couple with the acquisition 
of castrate resistant disease [14,15,21–23]. As cell line models studies demonstrate phosphorylation of 
serines 81, 308, and 650 in response to androgen treatment we hypothesis that these pathways drive 
kinases to phosphorylate and modulate AR activity. Cell cycle-dependent kinases (Cdk)1, 5 and 11 
have been implicated in the phosphorylation of serines 81 and 308 [24–26]. In addition, 
phosphorylation of serine 81 has been demonstrated to be associated with Cdk9. Cdk9 phosphorylation 
appears to selectively phosphorylate serine 81 to regulate promoter selectivity [11]. Phosphorylation of 
serine 308 has been associated with repression of AR activity by cyclin D3/Cdk11 [25]. Additionally, it 
has been observed using phosphospecific antibodies, that compartmentalization influences the 
phosphorylation state of AR and that there is a bias for androgen-dependent phosphorylation of serines 
81, 256, and 308 in the nucleus and androgen-independent phosphorylation of serine 94 in the 
cytoplasm; the authors suggest one function of nucleocytoplasmic shuttling is to integrate the signaling 
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environment in the cytoplasm with AR activity in the nucleus [26]. In the current study patients with 
high levels of nuclear pAR308 expression were observed to have a survival advantage over those 
patients with low expression. This observation is consistent with the previous observation that pAR308 
is associated with repression of AR activity and combined suggests that phosphorylation at this site 
may play a role in cell cycle arrest. It was surprising that levels of pAR308 expression increased with 
the development of CRPC disease when levels were associated with better prognosis, we hypothesis 
that as the disease progresses AR phosphorylation levels increase in response to signaling cascades 
being up-regulated, however due to the promoter selectivity associated with different phosphorylation 
sites this does not always result in advantage to the tumour. 
Serine 650 is phosphorylated in vitro by protein kinase A, protein kinase C and by members of the 
MAPK family, including the stress-induced kinases p38α and JNK [26]. Although phosphorylation of 
this residue is well documented, the functional consequences of this modification are a subject of 
debate. Initial studies reported a modest impairment of transactivation when the serine is mutated to 
alanine [20]. Yet others have observed no major changes in transactivation activity with the same 
mutation [27]. Gioeli et al. have demonstrated that serine 650 phosphorylation regulates nuclear 
export, with the non-phosphorylatable S650A mutant receptor retained in the nucleus and a 
concomitant increase in a target gene expression [25]. In addition it has been reported that serine 650 
phosphorylation is a target for protein phosphatase 1, and that it is involved in nuclear export and 
subsequent receptor turnover [24]. However in the present study, pAR650 expression was not associated 
with clinical outcome measures. 
Interestingly, phosphorylation of the AR at serine 791 was observed to be significantly associated 
with disease progression. High cytoplasmic protein expression (above the median) of pAR791 in 
hormone naïve tumours was observed to be significantly associated with a longer time to disease 
recurrence. High nuclear expression of pAR791 was also significantly associated with a longer time to 
death from disease recurrence in the castrate resistant tumours. Taken together these observations 
suggest high levels of AR phosphorylation at serine 791 have a beneficiary effect as patients are living 
longer. Due to this observation we further investigated whether high expression of pAR791 coincided 
with high apoptotic tumours or low proliferating tumours. Interestingly high pAR791 expression was 
significantly associated with disease specific survival from disease recurrence in patients with highly 
apoptotic tumours but this relationship was negated in tumours with low levels of apoptosis. Moreover, 
high pAR791 expression was significantly associated with disease specific survival from disease 
recurrence in patients with low proliferating tumours. Furthermore using the AR gene amplification 
data from this cohort it was possible to determine whether AR amplification resulted in increased 
protein expression and it was observed that pAR791 expression was significantly lower in castrate 
resistant patients with AR gene amplification. This result is in agreement with previous findings by Lin 
et al. who have demonstrated that AR is a substrate for Akt which phosphorylates the AR at serine 213 
and serine 791. Here the authors observed that only AR phosphorylation at serine 213 could inhibit AR 
transactivation thus inhibiting AR targets genes such as p21, which modulates androgen/AR-mediated 
apoptosis. This would provide a rationale along the observations from this study that following 
phosphorylation by Akt at serine 791, the AR induces cellular apoptosis which in turn leads to an 
overall survival advantage in a subset of prostate cancer patients. Moreover this study highlights a 
differential role of Akt phosphorylation on the AR. We have previously observed that pAR213 
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expression is associated with the development of CRPC and observed a strong correlation between 
pAkt473 and pAR213 [14]. However, in this study, a weak correlation was observed in the hormone 
naïve tumours between Akt activation and pAR791 (rs = 0.426, p = 0.034) but no correlation was made 
in the castrate resistant tumours. In addition when patients were split into AR amplification status it 
was observed that pAR213 expression was significantly higher in AR amplified tumours compared to 
non amplified tumours (p = 0.025) data not shown, whereas pAR791 expression is significantly lower 
in AR amplified tumours compared to non amplified tumours (p = 0.034). This data suggests that in 
the clinical setting another kinase may be responsible for phosphorylating the AR at serine 791. 
3. Experimental Section  
This biological marker study was performed in accordance to the reporting of tumour marker 
studies criteria (REMARK).  
3.1. Patients 
A total of 84 prostate cancer patients were included in this study, with hormone naïve and castrate 
resistant tumours from each patient available for analysis (168 tumours in total). All tumours had 
patient identification removed, and the clinical information database was anonymised. Ethical approval 
was obtained from the Multicentre Research Ethics Committee for Scotland (MREC/01/0/36) and 
Local Research and Ethical Committees. Patients were only selected for analysis if they initially 
responded to hormone treatment (in the form of sub capsular bilateral orchidectomy or LHRH 
aganosists combined with antiandrogens) but subsequently relapsed (2 consecutive rises in PSA 
greater than 10%) and had both a hormone naïve and castrate resistant tissue sample available for 
analysis. Hormone naive tissue was obtained from 18 patients by TRUS guided biopsy and the 
remaining by TURP and castrate resistant tumours were all obtained by TURP, which was carried out 
to relieve bladder outflow obstruction. 
3.2. Tissue Microarray (TMA) Construction 
Cores of prostate cancer tissue (4 × 0.6 mm2) as identified by a uropathologist were removed from 
representative areas of high Gleason grade and areas of low Gleason grade of formalin fixed paraffin 
embedded TURP blocks. These cores were then embedded into recipient array blocks that were 
constructed in triplicate. Therefore for each patient sample there is an area of high Gleason and low 
Gleason grade taken in triplicate that accounts for tumour heterogeneity within the sample. Control 
cores of normal prostate, colon, breast, pancreas, tonsil, kidney, liver and lung tissue were included in 
each TMA. 
3.3. Protein Expression Assessment 
3.3.1. Antibody Specificity 
pAR791 antibody was synthesised by CovalAb, Villeurbanne, France. In brief this included phospho 
peptide synthesis, HPLC and mass spectrometry analysis, conjugation to a carrier protein, pre-immuno 
Int. J. Mol. Sci. 2013, 14 16667 
 
 
bleed, immunisation of 2 specific pathogen free (SPF) rabbits, 3 boosts, 3 bleeds, ELISA titration of all 
sera and ELISA titration of purified serum. This antibody was made by immunising host animals with 
conjugated phosphorylated peptide, following the final bleed of the animal the phospho-specific 
antibodies were selected by affinity purification. Two affinity columns were used; the first column 
coupled with the non-phosphorylated peptide and the second column with the phosphorylated peptide. 
The serum then passed through the first column and the non-retaining elute kept and used for the 
second purification. The eluate was purified on the second column in order to remove antibodies which 
might recognise the un-phosphorylated peptide. ELISA tests were performed to ensure that the 
recovered antibody is phospho-specific. Antibody specificity for pAR94, pAR308 and pAR650.was 
previously confirmed using a peptide competing assay (Figure S1) [28]. 
3.3.2. Immunohistochemistry 
All immunohistochemistry was performed on TMAs with the exception of the TRUS biopsies 
which were 5 μm, archival formalin fixed, paraffin embedded prostate tumour sections on separate 
slides. Immunohistochemistry for pAR94, pAR308, pAR650 and pAR791 were performed as follows: 
Sections were dewaxed in xylene and rehydrated through graded alcohol. Antigen retrieval for all 
proteins was performed using heat treatment under pressure in Tris-EDTA buffer (5 mM Trizma Base, 
1 mM EDTA, pH 8) for 5 min. Endogenous peroxidase activity was blocked using 3% hydrogen 
peroxide and non-specific background staining was blocked using 5% horse serum in TBS for 20 min. 
pAR94 (Abcam, Cambridgeshire, UK), pAR308 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
pAR650 (Abcam, Cambridgeshire, UK), and pAR791 (CovalAb, Villeurbanne, France), antibodies were 
used at the following concentrations (2 μg/mL, 2 μg/mL, 4 μg/mL, and 50 μg/mL) diluted in Dako 
antibody diluent (Dako A/S). All antibodies were incubated overnight at 4 °C. Bound antibody 
complex was visualized using EnVision plus kit (Dako A/S) followed by 3,3-diaminobenzidine 
tetrahydrochloride (Vector Laboratories). Nuclei were counterstained with haematoxylin before 
mounting with DPX. A positive (tissue know to express the antigen) and a negative control (tissue 
known to not express the antigen, and positive control tissue with antibody replaced with isotyped 
matched antibody) were included in each immunohistochemistry run to exclude the possibility of  
false-negative and false-positive staining. Examples of staining expression patterns for all markers in 
both HNPC and CRPC tumours are shown in Figure 7. 
Ki67 immunohistochemistry was performed by established protocols in the Department of 
Pathology, Glasgow Royal Infirmary with appropriate positive and negative controls. Dako anti-Ki-67 
(monoclonal mouse anti-human, Ki-67 antigen, clone MIB1, code M7240, DAKO, Glostrup, 
Denmark) was used at dilution 1:100 for 30 min for immunohistochemistry on a Bond Max automated 
slide stainer (Leica Microsystems, Wetzlar, Germany) according to the manufacturer's instructions, 
with Leica Envision detection system. Slides were lightly counterstained with haematoxylin, dehydrated 
and mounted with DPX. Apoptotic scoring was performed as per manufacturers instructions using the 
R & D systems Tunel labeling kit (TdT in situ DAB) for light microscopy. 
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Figure 7. Prostate tumours displaying immunohistochemical staining of pAR94, pAR308, 
pAR650 and pAR791. The bar on each image represents 10 µm 
 
3.3.3. Scoring Method 
Tissue staining intensity was scored blind by 2 independent observers using a weighted histoscore 
method, also known as the Hscore system [29] for phosphorylated AR antibodies. Histoscores were 
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calculated from the sum of (1 × % cells staining weakly positive) + (2 × % cell staining moderately 
positive) + (3 × % cells staining strongly positive) with a maximum of 300. Proliferation scoring and 
apoptotic scoring was counting using the point count technique. The numbers of positive and negative 
tumour cells were counted visually and the percentage of positive cells expressed as a percentage of 
the total number of cells. The inter-class correlation coefficient (ICCC) for each protein was calculated 
to confirm consistency between observers and the mean of the two observers’ scores were used for 
analysis. Changes in staining between pre and post castrate resistant cases were defined as an increase 
or decrease out with the 95% confidence interval for the difference in inter-observer variation i.e., the 
mean difference between the histoscores that each observer assigns for protein expression plus 2 
standard deviations.  
3.4. Statistical Analysis 
All statistical analysis was performed using the SPSS version 18.0 for Windows. Protein expression 
data was not normally distributed and is shown as median and inter quartile ranges. Wilcoxon Signed 
Rank Tests were used to compare protein expression between pre and post castrate resistant tumours. 
Survival analyses were conducted using Kaplan-Meier method and curves were compared with the 
log-rank test. Hazard ratios (HR) were calculated using Cox Regression analysis. Multivariate analysis 
combined any significant proteins of interest with significant clinical parameters to establish if it was 
independent of these known prognostic markers in influencing patient outcome. 
4. Conclusions  
The findings presented in the current study expand upon our previous work describing the 
association of phosphorylated serine 213 in prostate cancer tumours and demonstrate that phosphorylation 
of AR can positively and negatively regulate AR actions. Taken together, this data indicates that 
phosphorylation of the AR has the potential to regulate AR function in the development and 
progression of CRPC and it is conceivable that the functional consequences of phosphorylation at 
individual serine residues maybe gene specific. Further work is necessary to distinguish these possibilities. 
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